French Paper and Forestry Products Stock News

ENXTPA:RNO
ENXTPA:RNOAuto

Renault’s SafeCycloMove V2X Trial And What It Means For Valuation

Renault took part in a large-scale live trial of the SafeCycloMove collision-prevention technology in urban traffic conditions. The project focused on real-world validation of vehicle to everything (V2X) systems aimed at improving road safety for cyclists and other vulnerable road users. The trial reported positive technical results that point to practical readiness for deployment in public transportation networks. For investors watching ENXTPA:RNO, this project arrives at a time when the...
ENXTPA:RI
ENXTPA:RIBeverage

A Look At Pernod Ricard (ENXTPA:RI) Valuation After Recent Share Price Rebound

Recent share performance and context Pernod Ricard (ENXTPA:RI) has caught investor attention after a recent share price move, with the stock showing contrasting results over shorter and longer time frames that may prompt a closer look at fundamentals. See our latest analysis for Pernod Ricard. The recent 1 month share price return of 13.49% and year to date share price return of 18.99% suggest momentum has picked up, even though the 1 year total shareholder return decline of 7.58% and 3 year...
ENXTPA:AM
ENXTPA:AMAerospace & Defense

Assessing Dassault Aviation (ENXTPA:AM) Valuation After Strong Recent Share Price Momentum

With no single headline event driving attention today, Dassault Aviation société anonyme (ENXTPA:AM) is drawing interest after a period of strong share price moves. This is prompting investors to reassess how its fundamentals line up with recent returns. See our latest analysis for Dassault Aviation société anonyme. The recent 7.2% 7 day share price return, building on a 10.0% 30 day and 33.0% 90 day share price return, comes on top of a 53.4% 1 year total shareholder return and leaves the...
ENXTPA:MMB
ENXTPA:MMBMedia

A Look At Lagardere (ENXTPA:MMB) Valuation After Record 2025 EBIT And Lower Net Debt

Lagardere (ENXTPA:MMB) is back in focus after releasing its full year 2025 results. The company reported higher sales, revenue, and earnings per share, along with a record adjusted EBIT and lower net debt. See our latest analysis for Lagardere. The earnings release comes after a period where short term share price momentum has been modest, with a 7 day share price return of 3.82% and a 1 year total shareholder return decline of 8.36%, hinting that the market is still weighing improved...
ENXTPA:ENX
ENXTPA:ENXCapital Markets

Euronext (ENXTPA:ENX) Valuation Check After Recent Share Price Moves And Premium P/E Multiple

Context for Euronext’s Recent Share Performance Euronext (ENXTPA:ENX) has drawn fresh attention after recent share price moves, with the stock up 4.8% over the past month but showing a 1.1% decline over the past 3 months. See our latest analysis for Euronext. Looking beyond the recent bounce, Euronext’s share price return over the past year has been more muted than its very large 3 year total shareholder return of about 7x. This suggests that earlier momentum has cooled even as investors who...
ENXTPA:NEX
ENXTPA:NEXElectrical

Assessing Nexans (ENXTPA:NEX) Valuation After Recent Share Price Volatility

Why Nexans is on investors’ radar today Nexans (ENXTPA:NEX) has attracted fresh attention after recent share price moves, with the stock showing mixed short term performance and stronger multi year total returns that may prompt investors to reassess the cable maker’s profile. See our latest analysis for Nexans. Recent trading has been choppy, with a 7 day share price return of an 8.36% decline and a relatively flat 30 day share price return of a 0.39% decline. However, the 1 year total...
ENXTPA:DIM
ENXTPA:DIMLife Sciences

A Look At Sartorius Stedim Biotech (ENXTPA:DIM) Valuation After Robust Full Year 2025 Results

Sartorius Stedim Biotech (ENXTPA:DIM) just released its full year 2025 results, reporting sales of €2,967.5m and net income of €265.6m, putting fresh financial data in focus for shareholders. See our latest analysis for Sartorius Stedim Biotech. The latest full year results land at a time when momentum has been mixed, with a 3.86% 1 day share price return and 4.46% 7 day share price return, compared with a 1 year total shareholder return of 10.25% and a 42.86% 3 year total shareholder return...
ENXTPA:SU
ENXTPA:SUElectrical

Assessing Schneider Electric (ENXTPA:SU) Valuation After EcoStruxure Foxboro SDA Automation Launch

Schneider Electric (ENXTPA:SU) has introduced EcoStruxure Foxboro Software Defined Automation, an open, software-defined distributed control system designed to tackle aging infrastructure, high operating costs, and modernization needs in hybrid and process industries. See our latest analysis for Schneider Electric. The EcoStruxure Foxboro SDA launch lands at a time when Schneider Electric’s 1 month share price return of 13.65% and 90 day share price return of 17.81% suggest firming momentum...
ENXTPA:EL
ENXTPA:ELMedical Equipment

Has The Recent Share Price Slide Opened An Opportunity In EssilorLuxottica (ENXTPA:EL)?

Wondering if EssilorLuxottica Société anonyme is fairly priced at its current level, or if the market is missing something about its long term potential. The share price closed at €238.20, with returns of 7.8% decline over the past week, 11.1% decline over the past month, and 10.3% decline year to date, while the 1 year return is 16.8% decline, compared with gains of 52.5% over 3 years and 90.7% over 5 years. These mixed return figures suggest that sentiment around the stock has shifted over...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Is Sanofi (ENXTPA:SAN) Pricing Reflect Its DCF Upside After Recent Share Price Weakness

If you are wondering whether Sanofi shares are offering fair value at around €79.58, you are not alone. This article is built to help you weigh what the current price might be saying. Over the past week the stock is up 2.5%, while the 1 year return sits at a 20.2% decline and the year to date return is a 3.3% decline, with a relatively flat 3 year return of 0.2% and a 5 year return of 27.9%. Recent headlines around Sanofi have focused on the broader healthcare and pharmaceuticals space,...
ENXTPA:ABVX
ENXTPA:ABVXBiotechs

Abivax ECCO Data Sharpen Obefazimod’s IBD Opportunity And Investor Focus

Abivax (ENXTPA:ABVX) presented new preclinical and clinical data for obefazimod at the ECCO Congress. The data highlighted anti fibrotic activity in Crohn's disease and rapid symptomatic relief in inflammatory bowel disease. Large Phase 3 trials were reported to show a strong safety profile and further validation of obefazimod's miR 124 targeting mechanism. Abivax focuses on inflammatory and autoimmune diseases, with obefazimod positioned as its lead asset in inflammatory bowel disease. For...
ENXTPA:AI
ENXTPA:AIChemicals

A Look At Air Liquide (ENXTPA:AI) Valuation After Higher Net Income And Dividend Proposal

L'Air Liquide (ENXTPA:AI) drew attention after reporting full year 2025 results, with net income of €3,517.9m on sales of €26,940.2m, alongside a proposed 12.1% higher dividend of €3.70. See our latest analysis for L'Air Liquide. The proposed 12.1% dividend increase and solid full year 2025 net income appear to have fed into recent optimism, with a 1 month share price return of 11.68% at €175.56 and a 5 year total shareholder return of 86.58%. This suggests that momentum has been building...
ENXTPA:TKO
ENXTPA:TKOCapital Markets

A Look At Tikehau Capital’s Valuation As Full Year 2025 Results Spark Fresh Investor Interest

Tikehau Capital (ENXTPA:TKO) has drawn fresh attention after reporting full year 2025 earnings, with net income of €136.4 million, a proposed €0.80 dividend per share, completed buybacks, and upcoming board changes. See our latest analysis for Tikehau Capital. The strong 1 day share price return of 6.88% to €17.10, alongside a 15.54% 3 month share price return, contrasts with a 1 year total shareholder return of 18.11% decline. This suggests recent momentum has not yet reversed longer term...
ENXTPA:FDJU
ENXTPA:FDJUHospitality

Assessing FDJ United’s Valuation After Earnings, Dividend Hike And 2026 Guidance Shift

Why FDJ United’s latest moves matter for shareholders FDJ United (ENXTPA:FDJU) is back in focus after a packed update, combining full year 2025 results, a proposed dividend increase, fresh 2026 guidance and senior leadership changes on the executive committee. For you as an investor, this mix of operational data, payout policy and management reshuffle helps frame how the business is being run and how shareholder returns are being approached over the coming year. See our latest analysis for...
ENXTPA:BN
ENXTPA:BNFood

Assessing Danone (ENXTPA:BN) Valuation After Recent Share Performance And Mixed Growth Expectations

Without a clear single news catalyst, Danone (ENXTPA:BN) tends to draw attention from investors through its recent share performance, dividend profile, and how its current valuation compares with its underlying fundamentals. See our latest analysis for Danone. At a share price of €73.6, Danone has recently seen a 7.82% 1 month share price return, while its year to date share price return is a 3.21% decline. The 1 year total shareholder return of 10.57% and 3 year total shareholder return of...
ENXTPA:KER
ENXTPA:KERLuxury

Kering (ENXTPA:KER) Valuation Check As Weak 2025 Results Pressure Earnings And Dividend

Kering (ENXTPA:KER) is back in focus after reporting full year 2025 results that showed sales of €14,675m and net income of €72m, sharply below the prior year’s figures. See our latest analysis for Kering. The weak 2025 earnings, the proposed lower ordinary dividend of €3.00 per share and the leadership change at Bottega Veneta have come against a backdrop of a 6.14% 90 day share price decline and a 44.92% 3 year total shareholder return loss. This signals pressure rather than momentum,...
ENXTPA:TTE
ENXTPA:TTEOil and Gas

TotalEnergies Balances Suriname Oil Bet With Renewables And EV Growth

TotalEnergies is committing multibillion euro capital to the GranMorgu oil project in Suriname, targeting low emission production in a country facing economic instability. The company has signed long term renewable power supply deals with major global technology firms, securing offtake for part of its clean energy portfolio. It is also partnering to roll out electric vehicle charging infrastructure across the Benelux region, expanding its presence in European mobility services. For...
ENXTPA:FDJU
ENXTPA:FDJUHospitality

FDJ United Targets Growth After Early Kindred Integration And Leadership Shift

FDJ United, listed as ENXTPA:FDJU, has completed the integration of Kindred ahead of schedule. The group has raised its long term targets following the integration. FDJ United has made changes to its executive team, including new leadership for Online Betting and Gaming and Group strategy. For you as an investor, FDJ United sits at the crossroads of lotteries, sports betting and online gaming, with Kindred now folded into the group earlier than planned. The sector has seen ongoing shifts...
ENXTPA:LOCAL
ENXTPA:LOCALInteractive Media and Services

Solocal Group (ENXTPA:LOCAL) Net Margin Collapse Challenges Bullish Earnings Narratives

Solocal Group (ENXTPA:LOCAL) has just posted its FY 2025 numbers, with second half revenue of €160.4 million and net income of €8.8 million, while the trailing twelve months show revenue of €324.5 million and net income of €14.2 million anchoring the earnings picture. The business has seen half year revenue move from €170.7 million in the second half of 2024 to €164.1 million in the first half of 2025 and then to €160.4 million in the latest period, alongside EPS of €5.47, €5.07 and €0.16...
ENXTPA:DBV
ENXTPA:DBVBiotechs

A Look At DBV Technologies (ENXTPA:DBV) Valuation As New VIASKIN Peanut Data Heads To AAAAI 2026

DBV Technologies (ENXTPA:DBV) is back in focus as it prepares to share fresh VITESSE Phase 3 data on its VIASKIN Peanut Patch at the 2026 AAAAI Annual Meeting, spotlighting peanut allergy treatment in young children. See our latest analysis for DBV Technologies. Those upcoming VITESSE Phase 3 readouts and recent conference appearances come after a sharp shift in sentiment, with the share price at €3.56, a 90 day share price return of 48.95% and a 1 year total shareholder return above 300%,...
ENXTPA:ICAD
ENXTPA:ICADREITs

Assessing Icade (ENXTPA:ICAD) Valuation After 2025 Results Show Lower Revenue But Narrower Net Loss

Why Icade’s latest earnings matter for shareholders Icade (ENXTPA:ICAD) has just wrapped up its 2025 financial year. The board met on 17 February 2026 to approve results that featured lower revenue but a smaller net loss. The group reported 2025 revenue of €1,449.6 million and sales of €346.5 million, both below the previous year. The net loss narrowed to €123 million, alongside a reduced loss per share from continuing operations. See our latest analysis for Icade. At a share price of €21.2,...
ENXTPA:NEX
ENXTPA:NEXElectrical

Is It Too Late To Consider Nexans (ENXTPA:NEX) After Its Strong Multi Year Run?

If you are wondering whether Nexans is still reasonably priced after its recent run, or if the value story has started to cool, this article is for you. The share price closed at €126.60, with a 9.8% decline over the past week, a 2.2% gain over the last 30 days, and returns of 21.4% over 1 year, 47.9% over 3 years, and 123.2% over 5 years. These moves have put valuation back in focus, especially for investors comparing the recent short term pullback with the stronger multi year returns. With...
ENXTPA:VK
ENXTPA:VKEnergy Services

Assessing Vallourec (ENXTPA:VK) Valuation After Its New Green Hydrogen Partnership With Baker Hughes

Vallourec (ENXTPA:VK) is back in focus after announcing a collaboration with Baker Hughes to combine its Delphy underground hydrogen storage solution with Baker Hughes compression technology for green hydrogen projects. See our latest analysis for Vallourec. The Baker Hughes agreement comes after a period of strong share price momentum for Vallourec, with a 30 day share price return of 17.18% and a year to date share price return of 22.53%, while the 3 year total shareholder return of 56.59%...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi (ENXTPA:SAN) One Off €3.4b Charge Tests Bullish Earnings Narratives

Sanofi (ENXTPA:SAN) has wrapped up FY 2025 with fourth quarter revenue of €12.2b and a basic EPS loss of €0.67, alongside trailing 12 month revenue of €46.7b and EPS of €4.05 that still reflect the impact of a large one off €3.4b charge. Over recent periods, revenue has moved between €10.6b and €14.2b a quarter, while basic EPS has ranged from €1.01 to €2.32 in the first three quarters of 2025 before this latest loss. This sets a mixed backdrop for the trailing 10.6% net margin versus 12.4% a...